Tests a community program for lenacapavir injections to prevent HIV
Tests lenacapavir injections for HIV prevention in Latine gay, bisexual and transgender adults.
Plain-language title generated from the registry record
Registry title: Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP
Key facts
- Where
- Durham, United StatesSee the site
- Phase
- Phase 4
Where in United States
- El Centro HispanoDurham, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Duke University
- Trial code
- NCT07218211
- Record updated
- 19 October 2026
- Original description
The purpose of this project is to test a culturally-tailored, community-delivered long-acting injectable PrEP (lenacapavir) program for Latine gay and bisexual men (GBM) and transgender women (TGW). The objective is to evaluate whether this intervention demonstrates greater persistence on lenacapavir for Latine GBM and TGW compared with what has been observed historically at the Duke PrEP Clinic.Read full original descriptionShow less
INCLUSION - Enhancing PrEP Uptake and Retention Among Latine Transgender Women and Gay, Bisexual, and Other Men Who Have Sex With Men in the South Using Long-Acting Injectable PrEP
The purpose of this project is to test a culturally-tailored, community-delivered long-acting injectable PrEP (lenacapavir) program for Latine gay and bisexual men (GBM) and transgender women (TGW). The objective is to evaluate whether this intervention demonstrates greater persistence on lenacapavir for Latine GBM and TGW compared with what has been observed historically at the Duke PrEP Clinic.
Inclusion: Participants must be assigned male sex at birth; Report sexual activity with a someone assigned male at birth OR identify as GBM or TGW; be HIV-negative; Identify as Hispanic and/or Latine ; Be able to provide informed consent in English or Spanish ; Be 18 years or older ; Weigh at least 77 lbs (35 kg) by self-reported weight; Interested in PrEP and willing to undergo the study procedures.
Exclusion: Individuals who are currently taking oral PrEP from another source and are not willing to switch to lenacapavir for PrEP for the duration of the study will also be excluded; Individuals taking a medication with a significant interaction with lenacapavir will be excluded from the study; Individuals living with HIV; Individuals who report a history of severe renal or hepatic disease or with clinical stigmata of either disease on physical exam as assessed by a study clinician will be excluded; Individuals assigned female sex at birth will be excluded.